These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 20644331)

  • 1. Effect of ezetimibe monotherapy on lipid metabolism and arterial stiffness assessed by cardio-ankle vascular index in type 2 diabetic patients.
    Miyashita Y; Endo K; Saiki A; Ban N; Nagumo A; Yamaguchi T; Kawana H; Nagayama D; Ohira M; Oyama T; Shirai K
    J Atheroscler Thromb; 2010 Oct; 17(10):1070-6. PubMed ID: 20644331
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bezafibrate Ameliorates Arterial Stiffness Assessed by Cardio-Ankle Vascular Index in Hypertriglyceridemic Patients with Type 2 Diabetes Mellitus.
    Yamaguchi T; Shirai K; Nagayama D; Nakamura S; Oka R; Tanaka S; Watanabe Y; Imamura H; Sato Y; Kawana H; Ohira M; Saiki A; Shimizu N; Tatsuno I
    J Atheroscler Thromb; 2019 Jul; 26(7):659-669. PubMed ID: 30584220
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of ezetimibe on remnant-like particle cholesterol, lipoprotein (a), and oxidized low-density lipoprotein in patients with dyslipidemia.
    Nozue T; Michishita I; Mizuguchi I
    J Atheroscler Thromb; 2010 Feb; 17(1):37-44. PubMed ID: 20075599
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of ezetimibe/simvastatin on lipoprotein subfractions in patients with primary hypercholesterolemia: an exploratory analysis of archived samples using two commercially available techniques.
    Ose L; Reyes R; Johnson-Levonas AO; Sapre A; Tribble DL; Musliner T
    Clin Ther; 2007 Nov; 29(11):2419-32. PubMed ID: 18158082
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effect of simvastatin, ezetimibe and their combination on the lipid profile, arterial stiffness and inflammatory markers.
    Efrati S; Averbukh M; Dishy V; Faygenzo M; Friedensohn L; Golik A
    Eur J Clin Pharmacol; 2007 Feb; 63(2):113-21. PubMed ID: 17200833
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of ezetimibe co-administered with simvastatin in thiazolidinedione-treated type 2 diabetic patients.
    Gaudiani LM; Lewin A; Meneghini L; Perevozskaya I; Plotkin D; Mitchel Y; Shah S
    Diabetes Obes Metab; 2005 Jan; 7(1):88-97. PubMed ID: 15642080
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Achieving lipoprotein goals in patients at high risk with severe hypercholesterolemia: efficacy and safety of ezetimibe co-administered with atorvastatin.
    Stein E; Stender S; Mata P; Sager P; Ponsonnet D; Melani L; Lipka L; Suresh R; Maccubbin D; Veltri E;
    Am Heart J; 2004 Sep; 148(3):447-55. PubMed ID: 15389231
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Atorvastatin 10 mg plus ezetimibe 10mg compared with atorvastatin 20 mg: impact on the lipid profile in Japanese patients with abnormal glucose tolerance and coronary artery disease.
    Uemura Y; Watarai M; Ishii H; Koyasu M; Takemoto K; Yoshikawa D; Shibata R; Matsubara T; Murohara T
    J Cardiol; 2012 Jan; 59(1):50-6. PubMed ID: 22100058
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of ezetimibe on remnant-like particle cholesterol in subjects with metabolic syndrome.
    Kotani K; Sakane N; Taniguchi N
    Med Princ Pract; 2012; 21(2):134-8. PubMed ID: 22024552
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of simvastatin and ezetimibe in lowering low-density lipoprotein cholesterol in subjects with type 1 and type 2 diabetes mellitus.
    Ciriacks K; Coly G; Krishnaswami S; Patel SB; Kidambi S
    Metab Syndr Relat Disord; 2015 Mar; 13(2):84-90. PubMed ID: 25490061
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The efficacy and safety of ezetimibe/simvastatin combination compared with intensified lipid-lowering treatment strategies in diabetic subjects with and without metabolic syndrome.
    Jimenez JG; Rosen JB; Pirags V; Massaad R; Hanson ME; Brudi P; Triscari J
    Diabetes Obes Metab; 2013 Jun; 15(6):513-22. PubMed ID: 23279632
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of Combination Therapy of Ezetimibe and Atorvastatin on Remnant Lipoprotein Versus Double Atorvastatin Dose in Egyptian Diabetic Patients.
    El-Tamalawy MM; Ibrahim OM; Hassan TM; El-Barbari AA
    J Clin Pharmacol; 2018 Jan; 58(1):34-41. PubMed ID: 28858387
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lipid-lowering effects of ezetimibe for hypercholesterolemic patients with and without type 2 diabetes mellitus.
    Okada K; Yagyu H; Kotani K; Miyamoto M; Osuga J; Nagasaka S; Ishibashi S
    Endocr J; 2010; 57(10):903-8. PubMed ID: 20733267
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Renal and vascular protective effects of ezetimibe in chronic kidney disease.
    Morita T; Morimoto S; Nakano C; Kubo R; Okuno Y; Seo M; Someya K; Nakahigashi M; Ueda H; Toyoda N; Kusabe M; Jo F; Takahashi N; Iwasaka T; Shiojima I
    Intern Med; 2014; 53(4):307-14. PubMed ID: 24531086
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effectiveness and safety of ezetimibe added to statin therapy in patients with primary dyslipidaemia not achieving the LDL-C treatment goal on statin monotherapy.
    González CA; Rubio-Guerra AF; Pavía A; Redding FJ; Cervantes JL; Zacarías JL; Yza R; Carranza J; Fernández P; Morales E; Robles FJ; Leyva JL; Rodríguez L
    Clin Drug Investig; 2007; 27(5):333-7. PubMed ID: 17451281
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cardio-ankle vascular index is superior to brachial-ankle pulse wave velocity as an index of arterial stiffness.
    Takaki A; Ogawa H; Wakeyama T; Iwami T; Kimura M; Hadano Y; Matsuda S; Miyazaki Y; Hiratsuka A; Matsuzaki M
    Hypertens Res; 2008 Jul; 31(7):1347-55. PubMed ID: 18957805
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Achievement of specified low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol apolipoprotein B, and high-sensitivity C-reactive protein levels with ezetimibe/simvastatin or atorvastatin in metabolic syndrome patients with and without atherosclerotic vascular disease (from the VYMET study).
    Robinson JG; Ballantyne CM; Hsueh W; Rosen J; Lin J; Shah A; Lowe RS; Hanson ME; Tershakovec AM
    J Clin Lipidol; 2011; 5(6):474-82. PubMed ID: 22108151
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Differential effects of fluvastatin alone or in combination with ezetimibe on lipoprotein subfractions in patients at high risk of coronary events.
    Stojakovic T; de Campo A; Scharnagl H; Sourij H; Schmölzer I; Wascher TC; März W
    Eur J Clin Invest; 2010 Mar; 40(3):187-94. PubMed ID: 20067513
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ezetimibe monotherapy ameliorates vascular function in patients with hypercholesterolemia through decreasing oxidative stress.
    Kurobe H; Aihara K; Higashida M; Hirata Y; Nishiya M; Matsuoka Y; Kanbara T; Nakayama T; Kinoshita H; Sugano M; Fujimoto E; Kurobe A; Sugasawa N; Kitaichi T; Akaike M; Sata M; Matsumoto T; Kitagawa T
    J Atheroscler Thromb; 2011; 18(12):1080-9. PubMed ID: 22027560
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of fluvastatin extended-release (80 mg) alone and in combination with ezetimibe (10 mg) on low-density lipoprotein cholesterol and inflammatory parameters in patients with primary hypercholesterolemia: a 12-week, multicenter, randomized, open-label, parallel-group study.
    Alvarez-Sala LA; Cachofeiro V; Masana L; Suarez C; Pinilla B; Plana N; Trias F; Moreno MA; Gambus G; Lahera V; Pintó X
    Clin Ther; 2008 Jan; 30(1):84-97. PubMed ID: 18343245
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.